Cargando…

Blood‐based biomarkers in Alzheimer's disease: Future directions for implementation

INTRODUCTION: Disease‐modifying therapies (DMTs) for Alzheimer's disease (AD) will increase diagnostic demand. A non‐invasive blood‐based biomarker (BBBM) test for detection of amyloid‐β pathology may reduce diagnostic barriers and facilitate DMT initiation. OBJECTIVE: To explore heterogeneity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suridjan, Ivonne, van der Flier, Wiesje M., Monsch, Andreas U., Burnie, Nerida, Baldor, Robert, Sabbagh, Marwan, Vilaseca, Josep, Cai, Dongming, Carboni, Margherita, Lah, James J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696162/ http://dx.doi.org/10.1002/dad2.12508

Ejemplares similares

Current Diagnostic Pathways for Alzheimer’s Disease: A Cross-Sectional Real-World Study Across Six Countries
por: Roth, Sophie, et al.
Publicado: (2023)

Alzheimer’s disease beyond amyloid: strategies for future therapeutic interventions
por: Shi, Jiong, et al.
Publicado: (2020)

Biomarkers in Alzheimer’s disease: role in early and differential diagnosis and recognition of atypical variants
por: Dubois, Bruno, et al.
Publicado: (2023)

Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
por: Sabbagh, Marwan N., et al.
Publicado: (2019)

New Acetylcholinesterase Inhibitors for Alzheimer's Disease
por: Mehta, Mona, et al.
Publicado: (2012)

Gray matter T1‐w/T2‐w ratios are higher in Alzheimer's disease
por: Pelkmans, Wiesje, et al.
Publicado: (2019)

Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimer’s Disease and Related Disorders
por: Sabbagh, Marwan N.
Publicado: (2017)

Broader Considerations of Higher Doses of Donepezil in the Treatment of Mild, Moderate, and Severe Alzheimer's Disease
por: Berk, Camryn, et al.
Publicado: (2012)

Novel Therapeutics in Alzheimer's Disease
por: Sabbagh, Marwan, et al.
Publicado: (2012)

For debate: substituting placebo controls in long-term Alzheimer's prevention trials
por: Spiegel, René, et al.
Publicado: (2011)

Editorial: A Time of Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies
por: Tousi, Babak, et al.
Publicado: (2021)

Using historical data to facilitate clinical prevention trials in Alzheimer disease? An analysis of longitudinal MCI (mild cognitive impairment) data sets
por: Berres, Manfred, et al.
Publicado: (2021)

Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology
por: Sabbagh, Marwan, et al.
Publicado: (2011)

Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer’s dementia?
por: Crum, Jana, et al.
Publicado: (2018)

Potential Peripheral Biomarkers for the Diagnosis of Alzheimer's Disease
por: Patel, Seema, et al.
Publicado: (2011)

5HT6 Antagonists in the Treatment of Alzheimer’s Dementia: Current Progress
por: Andrews, Megan, et al.
Publicado: (2018)

Diagnostic dilemmas in Alzheimer's disease: Room for shared decision making
por: van der Flier, Wiesje M., et al.
Publicado: (2017)

Exercise and Early-Onset Alzheimer's Disease: Theoretical Considerations
por: Hooghiemstra, Astrid M., et al.
Publicado: (2012)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

Grey matter network trajectories across the Alzheimer’s disease continuum and relation to cognition
por: Dicks, Ellen, et al.
Publicado: (2020)

Alzheimer's disease drug development pipeline: 2019
por: Cummings, Jeffrey, et al.
Publicado: (2019)

Alzheimer's disease drug development pipeline: 2020
por: Cummings, Jeffrey, et al.
Publicado: (2020)

Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
por: Stockmann, Julia, et al.
Publicado: (2020)

Is There Inflammatory Synergy in Type II Diabetes Mellitus and Alzheimer's Disease?
por: Lue, Lih-Fen, et al.
Publicado: (2012)

Establishing robust cognitive dimensions for characterization and differentiation of patients with Alzheimer's disease, mild cognitive impairment, frontotemporal dementia and depression
por: Beck, Irene R, et al.
Publicado: (2014)

Correction to: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
por: Stockmann, Julia, et al.
Publicado: (2021)

Microbleeds are associated with depressive symptoms in Alzheimer's disease
por: Leeuwis, Anna E., et al.
Publicado: (2017)

FDA position statement “Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry”
por: Sabbagh, Marwan N., et al.
Publicado: (2019)

The 12 Years Preceding Mild Cognitive Impairment Due to Alzheimer’s Disease: The Temporal Emergence of Cognitive Decline
por: Mistridis, Panagiota, et al.
Publicado: (2015)

Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit
por: Johnson, Sterling C., et al.
Publicado: (2023)

Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage
por: Poil, Simon-Shlomo, et al.
Publicado: (2013)

Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity
por: Jutten, Roos J., et al.
Publicado: (2021)

Associations between diffusion MRI microstructure and cerebrospinal fluid markers of Alzheimer's disease pathology and neurodegeneration along the Alzheimer's disease continuum
por: Moody, Jason F., et al.
Publicado: (2022)

Arylesterase Activity of Paraoxonase-1 in Serum and Cerebrospinal Fluid of Patients with Alzheimer’s Disease and Vascular Dementia
por: Romani, Arianna, et al.
Publicado: (2020)

Declining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study
por: Engels, Marjolein MA, et al.
Publicado: (2015)

Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods: A Systematic Review and Meta-analysis
por: Bocancea, Diana I., et al.
Publicado: (2021)

Microstate connectivity alterations in patients with early Alzheimer’s disease
por: Hatz, Florian, et al.
Publicado: (2015)

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
por: Duits, Flora H., et al.
Publicado: (2018)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

Hypertensive Disorders of Pregnancy Appear Not to Be Associated with Alzheimer's Disease Later in Life
por: Abheiden, Carolien N.H., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_p0daadf73oecpm3fceb3ab355k